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ENGLISH SUMMARY 
Brain abscess is a rare, but life-threatening infection. Epidemiological data on diseases 
remain the backbone for monitoring temporal changes and large-scale analyses of 
disease patterns in order to improve patient care. Current knowledge on the 
epidemiology and treatment of this serious condition relies almost exclusively on 
studies originating from departments of neurosurgery at tertiary care centres. 
Although informative on the clinical presentation of brain abscess, inherent 
limitations of such studies include selection bias and reduced generalisability. 
Moreover, most reports are hampered by short-term and incomplete follow-up, few 
are population-based or nationwide, and none provided control groups for analyses of 
risk factors or prognosis.  
The aim of the thesis is to 1) review the anti-infective treatment of brain abscess, 2) 
assess the positive predictive value (PPV) of brain abscess diagnosis codes in the 
Danish National Patient Registry, 3) examine and quantify risk factors for brain 
abscess, 4) estimate trends in incidence and 1-year mortality of brain abscess patients, 
and 5) investigate the long-term risks of mortality and epilepsy in brain abscess 
patients.  
This thesis is based on a narrative review and four epidemiological studies: a cross-
sectional study, a case-control study, and two cohort studies. For the review, we 
conducted a literature search of the United States National Library of Medicine 
(Pubmed) database and consulted well-known textbooks of infectious diseases as well 
as studies included in a previously published systematic review of brain abscess. For 
the epidemiological studies, we took advantage of the unique civil registration number 
assigned to all Danish residents to individually link data from nationwide and 
population-based registries (i.e. Danish Civil Registration System, the Danish 
National Patient Registry, and the Danish Pathology Database), and the department 
of clinical microbiology at Aalborg University Hospital. 
In study I, we confirmed that the preferred treatment regimen for community-
acquired brain abscess in immuno-competent individuals should be a 3rd generation 
cephalosporin combined with metronidazole.  However, these recommendations are 
based upon expert opinion and observational studies, and there is a need for 
prospective controlled studies to inform clinicians on the optimal anti-infective 
treatment of brain abscess. In study II, we found a crude PPV of 64% (95% CI 60-
68) for brain abscess diagnosis codes among 695 patients identified in the Danish 
National Patient Registry from 2007 through 2016. However, if patients were required 
to either have both a diagnosis and surgical procedure code for brain abscess or to be 
admitted with a primary diagnosis code of brain abscess without newly diagnosed 
central nervous system cancer, spondylodiscitis/intraspinal abscess, or procedure code 
for subdural empyema, then the PPV increased to 84% (95% CI 80-87). In study III, 
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we included 1,384 first-time brain abscess patients and 13,839 population controls 
matched by age, sex, and municipality code. Well-known risk factors of brain abscess 
were quantified and several novel risk factors identified (e.g. immuno-modulatory 
treatments) with adjusted odds ratios ranging from 2-20. In addition, population 
attributable fractions showed that neurosurgery (12%), solid cancer (11%), ear-nose-
throat infections (7%), and immuno-modulating treatments (5%) were substantial 
contributors to the burden of brain abscess on a societal level. In study IV, we 
observed a steady increase in the standardised incidence rate of brain abscess from 
0.60 per 100,000 person-years during 1982-88 to 0.90 per 100,000 person-years 
during 2010-16.  Increases in incidence were particularly notable among adults >40 
years of age as well as in the proportion of brain abscess patients with immuno-
compromise. The 30-day, 90-day, and 1-year mortalities were 7%, 13%, and 20% 
during 2010-16. Comparing mortality during 1982-88 with 2010-16 yielded an 
adjusted 1-year mortality rate ratio of 0.44 (95% CI 0.31-0.63). In study V, we 
compared the long-term prognosis of 1,384 brain abscess patients with 13,838 
population controls matched by age, sex, and municipality code. We observed 1-year, 
2-5 year, and 6-30 year hazard rate ratios of death of 17.5 (95% CI 13.9-22.0), 2.61 
(2.16-3.16), and 1.94 (95% CI 1.62-2.31). The increased mortality was significant 
across sex and age groups except subjects >80 years of age, and remained consistent 
in both previously healthy and immuno-compromised individuals. The cumulative 
incidence of new-onset epilepsy was 32% in brain abscess patients compared with 2% 
in their matched population controls.  
In conclusion, we substantiated current anti-infective treatment recommendations for 
brain abscess. However, evidence for these recommendations is sparse. We quantified 
known risk factors for brain abscess in addition to identification of several novel risk 
factors. The incidence of brain abscess is increasing and although the prognosis has 
improved during recent decades, 1-year mortality remains high and the lifetime risk 
of new-onset epilepsy is significant.
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DANSK RESUMÉ 
Hjerneabsces er en sjælden, men livstruende infektion. Epidemiologiske studier udgør 
hjørnestenen i overvågning af tidsmæssige variationer af sygdomme og kan bidrage 
med unik indsigt i sygdomsmønstre. Hidtidig viden om epidemiologiske forhold og 
behandlingen af hjerneabsces beror næsten udelukkende på studier udgående fra 
neurokirurgiske afdelinger på højt specialiserede sygehuse. Om end sådanne studier 
er nyttige vedrørende patienternes kliniske præsentation, er de også sårbare overfor 
selektions bias og har begrænset ekstern validitet. Yderligere har de fleste kun kort og 
ukomplet opfølgning af patienter, få er nationale eller befolkningsbaserede, og ingen 
af studierne inkluderer kontrolgrupper i analyser af risikofaktorer eller prognose. 
Formålet med denne afhandling er derfor at øge den nuværende viden gennem 1) at 
opsummere eksisterende data om behandling af hjerneabsces, 2) at undersøge den 
positive prædiktive værdi (PPV) af diagnosekoder for hjerneabsces i 
Landspatientregisteret, 3) at belyse og kvantificere risikofaktorer for hjerneabsces, 4) 
at evaluere forekomst og 1-års dødeligheden af hjerneabsces, og 5) at undersøge 
langtidsrisikoen for død og epilepsi blandt patienter med hjerneabsces. 
Denne afhandling bygger på et narrativt review, et tværsnitsstudie, et case-control 
studie og 2 kohortestudier. For at identificere relevante artikler til det narrative review, 
foretog vi en søgning i United States Library of Medicine (Pubmed) databasen og 
konsulterede kendte lærebøger såvel som referencer benyttet i et tidligere systematisk 
review. Til de register-baserede studier benyttede vi det unikke CPR-nummer i 
Danmark til at koble data på individniveau mellem diverse landsdækkende registre 
(Landspatientregisteret, CPR-registeret, og Dansk Patologi Register) samt Klinisk 
Mikrobiologisk Afdeling på Aalborg Universitetshospital. 
I studie 1 bekræfter vi, at den foretrukne empiriske behandling af samfundserhvervet 
hjerneabsces hos immunkompetente patienter bør være et tredjegenerations 
cephalosporin kombineret med metronidazol. Dog er hidtidige retningslinjer baserede 
på observationelle studier og eksperters vurdering, hvorfor prospektive og 
kontrollerede studier er absolut nødvendige for at øge vores viden om behandlingen 
af hjerneabsces. I studie II fandt vi, at den PPV for diagnosekoder for hjerneabsces 
var 64% (95% CI 60-68) blandt 695 patienter identificeret i Landspatientregisteret fra 
2007 til og med 2016. Dog kunne denne øges til 84% (95% CI 80-87), hvis vi kun 
inkluderede patienter med både en diagnose og procedure kode for hjerneabsces, eller 
kun inkluderede indlagte patienter med en primær diagnosekode for hjerneabsces 
uden samtidig nyligt diagnosticeret cancer i centralnervesystemet, 
spondylodiskitis/intraspinal absces eller subduralt empyem. I studie III inkluderede 
vi 1,384 hjerneabsces patienter og 13,839 befolkningskontroller matchet på køn, 
alder, og bopælskommune. Vi undersøgte og kvantificerede både kendte og nye 
risikofaktorer for hjerneabsces (f.eks. diverse immunmodulerende behandlinger) og 
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fandt justerede odds ratioer vekslende mellem 2-20. Yderligere analyser (population 
attributable fractions) viste, at neurokirurgi (12%), ikke-hæmatologisk cancer (11%), 
øre-næse-hals infektioner (7%) og immunmodulerende behandlinger (5%) bidrog 
væsentligt til forekomsten af hjerneabsces i Danmark. I studie IV observerede vi en 
stigning i den standardiserede incidens af hjerneabsces i Danmark fra 0.60 per 
100,000 person-år i perioden 1982-88 til 0.90 per 100,000 person-år i perioden 2010-
16. Stigningen i forekomsten var særligt udtalt blandt voksne >40 år og blandt andelen 
med hjerneabsces og nedsat immunforsvar. Herudover fandt vi en 30-dages, 90-dages 
samt 1-års dødelighed på henholdsvis 7%, 13% og 20% i perioden 2010-16. En 
sammenligning af starten af studieperioden (1982-88) og slutningen af studieperioden 
(2010-16) udmøntede sig en justeret 1-års mortalitets rate ratio på 0.44 (95% CI 0.31-
0.63). I studie V sammenlignede vi langtidsoverlevelsen og risiko for nyopstået 
epilepsi blandt 1,384 hjerneabscespatienter og 13,838 befolkningskontroller matchet 
på køn, alder, og bopælskommune. Vi fandt en 1-års, 2-5 års og 6-30 års hazard rate 
ratio for død på henholdsvis 17.5 (95% CI 13.9-22.0), 2.61 (2.16-3.16) og 1.94 (95% 
CI 1.62-2.31). Den øgede dødelighed var signifikant på tværs af køn og aldersgrupper, 
fraset ældre >80 år, og viste sig ensartet betydningsfuld blandt både tidligere raske og 
immunkompromitterede individer. Den kumulerede incidens for nyopstået epilepsi 
var 32% blandt hjerneabsces patienter og 2% blandt deres matchede 
befolkningskontroller. 
Sammenfattende viser vores studier, at den nuværende empiriske behandling af 
hjerneabsces er relevant, men svagt understøttet af kliniske studier. Endvidere 
bekræftes og kvantificeres kendte og nye risikofaktorer for hjerneabsces, og 
forekomsten af hjerneabsces vises at være højere end hidtil troet – og stigende. Om 
end dødeligheden for hjerneabsces er faldende gennem de seneste årtier, vedbliver 1-
års dødeligheden at være betragtelig ligesom livstidsrisikoen for nyopstået epilepsi. 
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CHAPTER 1. INTRODUCTION 
1.1. INTRODUCTION TO BRAIN ABSCESS 
Brain abscess is defined as an encapsulated mass of bacteria, necrotic tissue, and 
leukocytes within the brain parenchyma. The infection has been considered uniformly 
lethal until the first published description of a patient successfully operated by French 
surgeon S. F. Morand in 17521. Still, a review of published cases until 1872 concluded 
that only four of 214 surgically treated patients survived the infection2. The first real 
victory was accounted for in a landmark monograph by Sir William Macewen from 
Glasgow Royal Infirmary in 1893, in which the cure of 23 of 24 surgically treated 
brain abscess patients was described3.  
 
 
Portrait of Sir William Macewen adopted from Bowman, AK: The Life and Teachings of Sir William 
Macewen. A Chapter on the History of Surgery.4 
The results were attributed to the Scotsman’s profound knowledge of neuroanatomy, 
surgical skill, and adherence to the principles of aseptic surgery proposed by Joseph 
Lister5, which at the time was controversial. Demonstrating a profound understanding 
of infectious diseases from an early stage, he emphasized the pivotal requirement of 
prompt treatment: 
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“One might almost conclude that in uncomplicated abscesses of the brain 
operated on at a fairly early period, recovery ought to be the rule.”3 
Nonetheless, the overall mortality of brain abscess did not substantially improve until 
the introduction of antibiotic therapy into hospital care in the middle of the 20th 
century6. This was followed by further advances in the outcome of patients attributed 
to the implementation of computed tomography (CT) in the 1970s7 and stereotactic 
guided neurosurgery in the 1980s8,9. 
 
1.2. PATHOGENESIS AND PATHOPHYSIOLOGY 
Brain abscess occurs by invasion and encapsulation of bacteria, mycobacteria, or 
parasites within the brain parenchyma. The underlying mechanisms include cranial 
trauma with direct inoculation of bacteria into the brain, extension of infection from 
an adjacent cranial focus, and metastatic bacteraemic seeding from a distant source of 
infection. The predisposing condition of brain abscess remains unknown in about 19% 
of patients10.  
A landmark experimental study on the histologic evolution of brain abscess in dogs 
showed that the disease develops in four stages11:  
1. Early cerebritis stage (days 1-3) 
2. Late cerebritis (days 4-9) 
3. Early capsule formation (days 10-13)  
4. Late capsule formation (day 14 and later).  
Detailed histopathological examinations of the fully developed brain abscesses 
resulted in the characterisation of different zones from the centre to the periphery: 1) 
necrotic centre; 2) inflammatory cells, macrophages, and fibroblasts; 3) a dense 
collagenous capsule; 4) extensive vascularisation and cerebritis; 5) reactive 
astrocytes, gliosis, and cerebral oedema. 
 
1.3. INCIDENCE 
The incidence of brain abscess remains unclear and is suggested to range from 0.2 to 
1.9 per 100,000 person-years12-19. The reasons for this uncertainty comprise different 
definitions of brain abscess, large variations in study periods, the scarcity of health 
care settings with access to high-quality nationwide and population-based data 
sources, difficulties in confirming the clinical diagnosis in some cases, and presumed 
low prioritisation within research communities. Thus, estimates of the occurrence of 
 
19 
brain abscess relies almost exclusively on historical single-centre reports of a limited 
number of patients from departments of neurosurgery with inherent selection and 
publication bias. At the onset of the studies included in this thesis, there were only a 
limited number of population-based cohort studies to document the incidence of brain 
abscess, of which two were nationwide (Table 1).  
Based on previous literature, the incidence of brain abscess seems to have decreased 
during the last century due to improved care of chronic ear-nose-throat infections16,20 
along with decreases in the occurrence of severe head trauma2,5 and in the prevalence 
of patients with congenital heart disease21. Concordantly, comparisons within and 
between different health-care settings also suggest that the incidence of brain abscess 
seems to decrease according to improvements in the overall socio-economic status of 
societies14,22,23.  
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1.4. PATHOGENS 
Brain abscess can be caused by bacteria, mycobacteria and branch-forming bacteria 
(nocardia and actinomyces spp.), fungi, and parasites. Historically, streptococcal and 
staphylococcal species have been the predominant pathogens2,5. This is confirmed in 
a large meta-analysis from 2014 comprising all published studies of brain abscess 
since 197010 and in unpublished data from the Danish Study Group of Infections of 
the Brain (DASGIB) of all Danish patients with brain abscess from 2007 through 2016 
(Table 2). However, it appears that staphylococcal spp. have become less frequent in 
developed countries in recent decades15,16.  
 
Table 2: Causative pathogens of brain abscess. 
 DASGIB* 
Study period 2007-2016 
Study population All persons admitted in 
Denmark during the 
study period  
Patients with positive culture/identification 345/444 (78) 
Oral cavity bacteria (e.g. viridans streptococci, 
fusobacteria, anaerobic bacteria) 
208 (47) 
Other streptococcal spp.  
   S. pneumoniae 10 (2) 
   Enterococci 6 (1) 
   Beta-haemolytic streptococci 5 (1) 
Staphylococcus aureus 27 (6) 
Skin-colonizing bacteria (Propionibacteria, 
coagulase-negative staphylococci, corynebacteria) 
14 (3) 
Gram-negative enteric (Proteus spp., klebsiella 
spp., Escherichia coli) 
12 (3) 
Listeria monocytogenes 8 (2) 
Pseudomonas spp. 4 (1) 
Actinomycetales 15 (3) 
   Nocardia spp. 12 (3) 
   Actinomyces spp. (mono-culture) 2 (0.2) 
   Mycobacterium tuberculosis 1 (0.2) 
Fungi 16 (4) 
Parasites (Toxoplasma gondii) 11 (2) 
Other 8 
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* Unpublished data from Danish Study Group of Infections of the Brain (DASGIB) obtained by medical 
record review of all Danish adults with an ICD-10 diagnosis code for brain abscess in the Danish National 
Patient Registry from 2007-2016. 
Using state-of-the-art bacterial DNA sequencing from brain abscesses, studies have 
shown that almost all brain abscesses caused by oral cavity bacteria and those 
associated with ear-nose-throat infections are polymicrobial and include anaerobic 
bacteria24-26. Notable exceptions to these findings are brain abscesses caused by S. 
aureus, Pseudomonas aeruginosa, Listeria monocytogenes, or nocardial species. 
Fungal brain abscess is most often caused by aspergillus species27 and parasitic brain 
abscess by Toxoplasma gondii28,29. The causative pathogen remained unknown in 
about one third of brain abscess patients in a large meta-analysis10 although data in 
Table 2 suggest that this has decreased to approximately 23% in Denmark. 
 
1.5. RISK FACTORS 
Risk factors for brain abscess can be categorised according to pathogenic pathway and 
host conditions (Figure 2). 
 
Figure 2: Risk factors for brain abscess in humans.  
 
The relative importance of suggested risk factors varies between health-care settings 
and may be associated with certain pathogens. In less developed settings with limited 
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resources, predominant risk factors seem to be head trauma5,22, chronic ear-nose-
throat infections5,6,20,22,23, Human Immunodeficiency Virus (HIV)22, and cyanotic 
congenital heart disease30,31. This is in contrast to more developed countries, where 
previous neurosurgery, immuno-compromising conditions, and dental infections are 
significant risk factors15,16,32. 
Risk factors for brain abscess have predominantly been inferred by studies of patients 
admitted with brain abscess at departments of neurosurgery with inherent risks of 
selection bias. In addition, these studies were hampered by limited sample size and 
many examined more historical study populations. None of the studies were able to 
validate and quantify risk factors by comparisons with control populations or to 
estimate how much each risk factor contributes to the occurrence of brain abscess on 
a societal level (i.e. population attributable risks). 
 
1.6. SYMPTOMS AND SIGNS 
Symptoms and signs of brain abscess are often surprisingly modest and undramatic at 
admission. Headache is the most common symptom and occurs in 69% of patients, 
while fever is observed in 53% of patients10. Neurological deficits are present in 48% 
of patients and correlate with the anatomic localisation of the brain abscess and 
surrounding oedema. Other symptoms include nausea (47%), altered consciousness 
(43%), and seizures (25%). Only 20% of patients present with the classic triad of 
fever, headache, and focal neurological deficits10. Eventually, the abscess may rupture 
into the ventricles or onto the surface of the brain (2-35%)33-37, causing immediate and 
serious deterioration of the patients’ clinical condition and need for treatment at the 
intensive care unit. Rupture is often preceded by intense headache and syncope 
followed by meningeal reactions caused by the resultant subdural inflammatory 
response. Blood tests are usually unremarkable with normal levels of c-reactive 
protein observed in 40% of patients10.  
 
1.7. DIAGNOSIS 
The diagnostic work-up for brain abscess includes cranial CT or magnetic resonance 
imaging (MRI), a neurosurgical procedure, and microbiological examinations of brain 
abscess material, blood, and other (contiguous or distant) foci of infection.  
A tentative diagnosis of brain abscess is usually based upon the presence of a mass 
lesion on cranial CT or MRI in patients presenting to hospital with headache or a 
neurological deficit. MRI has been shown to be superior to CT in differentiating brain 
abscess from tumours, especially for mass lesions that are hyperintense on diffusion-
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weight imaging (DWI) and hypodense on apparent diffusion coefficient (ADC) 
sequences. This combination yields a sensitivity and specificity of 96% each,38 
although the value of DWI in post-operative brain abscesses may be limited 39.  
However, a definite diagnosis of brain abscess requires neurosurgical aspiration or 
excision of brain abscess material. Besides confirming the diagnosis, the procedure 
also provides essential information on causative pathogen(s) and their antibiograms 
in addition to therapeutic reduction of brain abscess volume. Microbiological 
examinations of abscess material consist of aerobic and anaerobic cultures40,41 and 
may include bacterial DNA sequencing methods 24-26. 
Blood cultures are positive in 28% of patients. CT of the thorax and abdomen are 
often valuable for diagnosis of a distant focus of infection or in patients at risk of 
fungal (aspergillosis) brain abscess42. Serological analyses are occasionally helpful, 
especially for diagnosis of CNS toxoplasmosis in persons with HIV27,43. Although 
lumbar puncture is contraindicated in patients with brain abscess due to risks of brain 
shift, the procedure is sometimes performed early during admission in everyday 
medical practice before the diagnosis of brain abscess is made10,43,44. The diagnostic 
yield of CSF cultures is limited with only 24-40% turning out positive, while clinical 
deterioration attributed to lumbar puncture has been observed in 2-7% of patients10,44. 
 
1.8. TREATMENT 
Treatment of brain abscess is a multi-disciplinary endeavour involving infectious 
diseases specialists, neurosurgeons, neuroradiologists, and clinical microbiologists. 
Key interventions include a combined diagnostic and therapeutic neurosurgical 
procedure and high-dose antimicrobial therapy for 6-8 weeks43. 
Stereo-tactically guided aspiration of brain abscess is now the preferred surgical 
technique compared with excision. Obvious advantages include the less invasive 
nature and tissue sparing nature of the procedure as well as the ability to reach 
abscesses located in eloquent or hard-to-reach areas of the brain. Although vulnerable 
to selection and publication bias as well as confounding by indication, a systematic 
review of studies of brain abscess from 1990 through 2008 found that aspiration was 
associated with decreased mortality compared with excision (7% vs. 13%)45. 
Currently, excision is reserved for brain abscesses located superficially or in the 
posterior fossa, and for those caused by difficult-to-treat pathogens such as nocardia 
and fungi43. 
To date, no randomised controlled trials exist to guide antibiotic treatment of bacterial 
brain abscess. Current guidelines are mainly based on a combination of expert opinion 
and retrospective data from single neurosurgical centres. Historically, the preferred 
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empiric treatment regimens consisted of high-dose intravenous benzylpenicillin and 
chloramphenicol with the addition of metronidazole in the late 1970’s46. This has 
since been replaced by a 3rd generation cephalosporin47,48 combined with 
metronidazole in immuno-competent patients20,43,49-52. For immuno-compromised 
individuals or depending on exposures, the addition of trimethoprim-
sulfamethoxazole (TMP-SMX), voriconazole, and anti-mycobacterial agents should 
be considered. For patients with recent neurosurgery or those at risk for methicillin-
resistant S. aureus (MRSA) infection, vancomycin should be included.  
 
1.9. PROGNOSIS 
The prognosis of brain abscess has improved substantially since the remarkable and 
pioneering efforts of Sir William Macewen. Case fatality has decreased from 40-70% 
to 5-10% for community-acquired bacterial brain abscess in immuno-competent 
patients in recent decades12-19,23, and seems only slightly higher in published studies 
from countries with more limited health-care resources,22,53-55 although exceptions do 
exist35,56,57 (Table 3). Of note, selection and publication bias may be particularly 
relevant in these settings. A few recent studies detailed standardised and complete 
follow-up with 1-year mortality rates of 11% and 19%15,18. Case fatality among 
patients with post-operative brain abscess has been reported to be 21%58 with higher 
mortality in patients with difficult-to-treat pathogens or severe immuno-
compromise59-63. Long-term sequelae include neurological deficits in approximately 
30% of survivors10. 
Epilepsy has a substantial impact on patient’s lives due to the nature and treatment of 
the disease64 and has been reported to occur in approximately 15-72% of survivors of 
brain abscess (Table 4). The epileptic substrate is likely scar tissue within the brain 
parenchyma as a consequence of the infection – while the contribution of any 
neurosurgical procedure is unknown.  
Recurrence of brain abscess has been reported to occur in 0-8% of patients in recent 
decades15,23,65-68, and is likely associated with unresolved or irreversible predisposing 
conditions.  
Similar to estimates of incidence and risk factors for brain abscess, studies on 
prognosis are mostly single-centre and of limited sample size. Generally, they lack 
complete long-term follow-up and fail to provide comparison cohorts to better detail 
the effect of brain abscess on the outcome.  
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1.10. AREAS OF UNCERTAINTY 
The rarity of brain abscess has largely precluded the development of evidence-based 
treatment recommendations. Thus, numerous areas of uncertainty remain and should 
ideally be addressed in future large-scale international research collaborations. This 
includes the establishment of reliable and reproducible animal models, further 
investigations into the pathogenesis of brain abscess, and standardised 
pharmacokinetic studies of intra-cavitary penetration of oral and intravenous 
antibiotics. Moreover, comparative studies of different antibiotic regimens and 
treatment durations32,48,76-78 as well as neurosurgical techniques45 are important 
unanswered clinical questions. Although a few studies have examined the usefulness 
of continuous drainage and irrigation of brain abscess with or without intra-cavitary 
antibiotic treatment3,79-81, such issues should also be explored further in animal studies 
and properly controlled clinical trials. Finally, unravelling the role of adjunctive 
dexamethasone82-84 and anti-convulsive treatment34,72,74,75 is of interest in order to 
improve medical care of this devastating disease.
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CHAPTER 2. OBJECTIVES 
The purpose of this thesis was to conduct studies of the incidence, risk factors, 
treatment, and long-term prognosis of brain abscess. Specific objectives of included 
studies were as follows:  
 
Study I Anti-infective treatment of brain abscess. To review studies describing the 
anti-infective treatment of brain abscess including animal models, pharmacokinetic 
data, and clinical studies. 
Study II Positive predictive (PPV) value of ICD-10 diagnosis codes for brain abscess 
in the Danish National Patient Registry. To examine the PPV of ICD-10 diagnosis 
codes for brain abscess in the Danish National Patient Registry from 2007 through 
2016. 
 
Study III Risk factors of brain abscess: a nationwide-population-based nested case-
control study. To examine and quantify risk factors for brain abscess and estimate 
population-attributable fractions compared with matched population controls. 
 
Study IV Incidence and mortality of brain abscess in Denmark: a nationwide 
population-based study. To examine temporal trends in the incidence of brain abscess 
in Denmark from 1982 through 2016 as well as 1-year mortality. 
 
Study V Long-term mortality and epilepsy in patients after brain abscess. To examine 
the long-term mortality and cumulative incidence of epilepsy in patients with brain 
abscess compared with matched control cohorts. 
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CHAPTER 3. MATERIALS & METHODS 
3.1. DATA SOURCES 
Study I 
The PubMed database is a public resource for biomedical literature managed free of 
charge by the United States National Library of Medicine. Other sources used were 
highly regarded textbooks of infectious diseases51,52 and the database of a previously 
published systematic review and meta-analysis of studies on brain abscess between 
1970 and 201310. 
Studies II-V 
The Danish Civil Registration System was established in 1968 as an administrative 
database to ease taxation and keep track of the Danish population85,86. The registry 
individually catalogued all persons living in Denmark (1968) and Greenland (1972), 
and since then every live born child and new inhabitants have been included as 
required by law86. At the time of this thesis, approximately 9.8 million persons have 
been cumulated in the registry87 with more than 400 million person-years of 
observation and less than 0.3% of persons lost to follow-up85. 
The registry keeps track of the unique 10-digit Central Person Registration (CPR) 
number assigned to all Danish residents at birth or immigration (Figure 3). 
 
 
Figure 3: Elements of the Danish Central Person Registration (CPR) number. 
 
The date of birth constitutes the first six digits and the remaining four numbers are 
used to distinguish persons born on the same date. Digits 5-7 indicate the year and 
century of birth, while the last number identifies the sex of the individual (even for 
EPIDEMIOLOGY OF BRAIN ABSCESS 
34
 
females; odd for males). This personal identifier cannot be used for any other 
individual in the future, even if the index person has died, emigrated, changed sex, or 
has been included into a witness protection programme87.  
Besides storing the names and CPR-numbers of all Danish residents, The Danish Civil 
Registration System also contains information on the vital and migration status on a 
day-to-day basis, address, citizenship, kinship (i.e. CPR numbers of parents, siblings, 
and children for all individuals born after 1952),86 marital status, voting rights, and 
membership of the Evangelical Lutheran Church in Denmark85,86. 
The quality of the data in the registry is considered very high, because of its 
continuous use and validation by public institutions for contact with Danish residents 
including all health care services86,88. This allows for unambiguous linkage of 
information on individuals between registries (Figure 4).  
 
Figure 4: Data sources used for studies II-V. 
 
The Danish National Patient Registry was founded in 1977 by the Danish Board of 
Health to keep track of the activity of Danish hospitals89,90. The registry holds 
information on all somatic hospital admissions since its establishment and was 
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expanded to include outpatient, psychiatric, and emergency department contacts since 
1995.  
For each patient contact, a primary diagnosis code and up to 20 secondary diagnosis 
codes is assigned by the attending physician and stored in the registry. This coding 
has been in accord with the World Health Organization’s International Classification 
of Diseases (ICD) version 8 until 1994 when it was replaced by ICD-10. Likewise, 
surgical procedures have been notified to the registry using the Danish Classification 
of Surgical Procedures from 1977 through 1995 and by a Danish version of the Nordic 
Medico-Statistical Committee Classification of Surgical Procedures since then89. In 
addition to  name, CPR number and diagnosis and procedure code(s) for each patient 
contact, the registry contains information on residence, department and hospital of 
admission, dates of admission and discharge, and admission type (acute versus non-
acute)89. Certain in-hospital medical treatments such as chemotherapy and biological 
treatments have also been mandatorily included in the registry since 200189. 
Although primarily intended as an administrative governmental database, the Danish 
National Patient Registry is increasingly being used for research91. An essential 
prerequisite for this purpose is a high validity and completeness of the included 
information, especially diagnosis codes. To this end, data sent to the registry from 
hospitals is automatically checked for missing (primary) codes, incorrect digits, 
erroneous CPR numbers, and discrepancies between diagnoses and sex (e.g. males 
cannot be assigned a diagnosis code of ovarian cancer)89. The Danish Board of Health 
have formally confirmed the quality of the registry at several occasions using medical 
record review as reference89,92. The positive predictive value of a large variety of 
medical diagnoses was found to be 81% at the three-digit level using either the 
primary or two secondary diagnosis codes89. In addition, by 2015 at least 114 studies 
had examined various codes and found PPVs ranging from <15% to 100%89. 
However, the majority of studies showed PPVs >80% including codes used to 
compute the Charlson Comorbidity Index score89,93. Nonetheless, researchers should 
critically assess the accuracy of diagnosis codes when using the registry for health-
care research. 
The Danish Pathology Registry contains all pathology reports in Denmark since 
1997, but extends to 1970’s and 1980’s in the four centres with neurosurgical 
departments94. Pathological diagnoses contained in this registry are catalogued 
according to the Danish Systemized Nomenclature of Medicine (SNOMED) codes. 
The electronic medical records at the Department of Clinical Microbiology, Aalborg 
University Hospital, is used in everyday clinical management of patients. Moreover, 
the system has been used for research purposes for a large prospective observational 
database on bacteraemia in North Denmark Region since 199295. 
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3.2. STUDY POPULATION 
Brain abscess patients (n=1,384). 
Patients with a first-time hospital diagnosis of brain abscess in the period 1982 
through 2016 were identified in the Danish National Patient Registry. The date of 
admission for first-time hospitalisation for brain abscess was considered the index 
date. Patients with subdural empyema were excluded as were those with newly 
diagnosed central nervous system (CNS) tumour, intraspinal abscess, or 
spondylodiscitis within 90 days of admission for brain abscess.  
Population comparison cohort for case-control study (n=13,839). 
We used the Danish Civil Registration System and Danish National Patient Registry 
to randomly identify 10 persons for each case individually matched by age, sex, and 
municipality code on the index date. In addition, population controls had to be alive 
and without a brain abscess diagnosis code at time of matching. Population controls 
were allowed to serve as controls for several cases if selected as such by chance. Using 
this risk-set sampling approach, odds ratios can be considered equivalent to incidence 
rate ratios96. 
Population comparison cohort for cohort study (n=13,838). 
We used the Danish Civil Registration System and Danish National Patient Registry 
to identify 10 persons for each case individually matched by age, sex, and 
municipality code on the index date. In addition, population controls had to be alive 
and without a diagnosis code for brain abscess at time of matching. Population 
controls could only serve as controls for one case each. 
Appendicitis comparison cohort for cohort study (n=6,887). 
We used the Danish Civil Registration System to identify all persons with a diagnosis 
of appendicitis within one month of the index date for each brain abscess patient. From 
this cohort, we randomly selected five appendicitis controls for each case individually 
matched by age (+/- 5 years) and sex on the index date (+/- 1 month). Appendicitis 
controls had to be alive and without a diagnosis code for brain abscess at time of 
matching. Finally, appendicitis controls could only serve as controls for one case each. 
Siblings for cohort study (n=1,034 for cases and n=10,025 for controls). 
Siblings of patients and population controls from the cohort study were identified 
using the Danish Civil Registration System. 
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3.3. STUDY DESIGNS AND OUTCOMES 
Study designs in this thesis include a narrative review (Study I), a cross-sectional 
study (Study II), a case-control study (Study III), an open and closed unmatched 
cohort study (Study IV), and a closed matched cohort study (Study V).  
 
Figure 5: Study designs used in this thesis. 
 
The primary outcome in each study were: 
Study I Comprehensive summary of studies examining anti-infective treatment 
of brain abscess. 
Study II The PPV of brain abscess diagnosis codes in the Danish National Patient 
Registry. 
Study III Estimates of relative risks (i.e. odds ratios) of suggested known as well 
as novel risk factors and their population attributable fractions. 
Study IV The incidence of brain abscess as well as 30-, 90-day, and 1-year 
mortality. 
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Study V Time from study inclusion to death and cumulative incidence of epilepsy 
in brain abscess patients compared with their matched population controls. 
 
3.4. STATISTICAL ANALYSES 
Estimates of incidence (Study IV) 
Estimates of incidence of brain abscess were examined by direct standardisation using 
the Danish population in year 2016 as reference. Next, temporal changes were 
assessed by incidence rate ratios (IRR) with 95% confidence intervals (CI). A two-
source capture-recapture analysis was conducted in North Denmark Region using the 
Danish National Patient Registry as the primary source and the electronic record 
system at the Department of Clinical Microbiology, Aalborg University Hospital as 
the secondary source. In a supplementary analysis, we also searched the Danish 
Pathology Registry for any missed cases. 
Observation time (Studies III-V) 
The index date was defined as first date of hospitalisation with brain abscess for 
patients as well as their matched population controls and sibling cohorts.  
For the case-control study, all exposures from January 1, 1982 until the day before the 
index date were registered, except for head trauma, ear-nose-throat infections, and 
dental infections for which the index date was included. 
For the cohort studies, we calculated the observation time from the index date to date 
of death, emigration, loss to follow-up, or January 1, 2017, whichever came first. 
However, for appendicitis controls we used the date of admission for appendicitis as 
the index date to compute observation time. 
Kaplan-Meier survival analyses (Studies IV and V) 
Survival was illustrated by Kaplan-Meier curves 
Regression analyses (Studies III-V) 
Crude and adjusted odds ratios for suggested risk factors of brain abscess were 
examined by conditional logistic regression. We used Cox regression analyses to 
compute unadjusted and adjusted mortality rate ratios (MRR) with 95% confidence 
intervals (CI). For all exposure variables, the proportional hazards assumptions were 
confirmed visually by log(-log(survival function)) against time. 
Cumulative incidence function (Study V) 
Cumulative incidence of epilepsy with 95% CIs was assessed by taking into account 
competing risks of death, emigration, and loss to follow-up. 
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CHAPTER 4. RESULTS 
4.1. STUDY I  
A search on studies of anti-infective treatment of brain abscess identified 546 articles 
in the PubMed database (Figure 6). Of these, the majority were excluded by title, 
abstract, or article content leaving 145 studies for further consideration. Next, 
additional studies were identified by a cited reference search and consultation of 
infectious diseases textbooks51,52 as well as the database of a previously published 
systematic review and meta-analysis10. Since this was a narrative review combined 
with limitations imposed by the publisher on the number of references, we included 
113 studies that we considered important for discussion in this review. 
 
 
Figure 6: Literature search for narrative review on anti-infective treatment of brain abscess. 
In general, animal models and clinical studies examining the anti-infective treatment 
of brain abscess are scarce. This applies for both choice of drugs, route and duration 
of therapy, as well as adjunctive treatments including dexamethasone. The existing 
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pharmaco-kinetic studies of intra-cavitary penetration of anti-infective drugs are 
mostly characterised by random ad hoc measurements in a limited number of patients 
early during treatment – mostly with drugs rarely used today. There are no randomised 
controlled trials of treatment of brain abscess.  
Based upon the available literature to date, the suggested empirical and targeted anti-
infective treatments are described in Table 5. 
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4.2. STUDY II 
We identified 709 patients with a primary or secondary diagnosis code for brain 
abscess in the Danish National Patient Registry from 2007 through 2016. Of these, 
the medical records could be retrieved for 694 patients and 444 were confirmed to 
have had a brain abscess.  
Positive predictive value (PPV). The overall PPV of diagnosis codes for brain 
abscess was 64% (95% CI 60-68) and ranged from 24% to 96% between different 
diagnosis codes. However, the PPV increased to 84% (95% CI 80-87) by applying an 
algorithm in which patients were only included if: 
1) They had a diagnosis and surgical procedure code for brain abscess 
Or 
2) They had been admitted with a diagnosis code of DG060 (C, E, F) or 
DG079B without a newly diagnosed CNS cancer, spondylodiscitis or 
intraspinal abscess. In addition, these patients were omitted if they had a 
procedure code for intracranial empyema.  
The algorithm successfully identified 89% (395/444) of patients with brain abscess 
confirmed by medical record review. 
 
4.3. STUDY III 
During the study period (1982-2016), we identified 1,384 brain abscess patients of 
which 37% were female and the median age was 50 years (interquartile range 33-63). 
In general, brain abscess patients had more comorbidity assessed by the Charlson 
Comorbidity Index score >2 than matched controls. 
Adjusted odds ratios ranged from 2-20 for diabetes mellitus and previous 
neurosurgery, respectively (Figure 7).  
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Figure 7: Risk factors for brain abscess and population attributable fractions. Adopted from Bodilsen J, 
Dalager-Pedersen M, van de Beek D, Brouwer MC, Nielsen H. Risk Factors for Brain Abscess: A 
Nationwide, Population-Based, Nested Case-Control Study. Clin Infect Dis. 2019 Oct 23;371:447–7. 
 
The odds ratios were stable for all examined exposures throughout the study period, 
except ear-nose-throat infection for which the associated risk decreased in recent 
decades. Immuno-modulating treatments emerged as novel significant risk factors. 
Population attributable fractions suggested that neurosurgery (12%), solid cancer 
(11%), ear-nose-throat infections (7%), and immuno-modulating treatments (5%) 
were important risk factors on a societal level.  
 
4.4. STUDY IV 
In Denmark, we observed a steady increase in the incidence of brain abscess from 
0.60 per 100,000 person-years during 1982-88 to 0.90 per 100,000 person-years 
during 2010-16 (Figure 8). 
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Figure 8: Incidence of brain abscess in Denmark from 1982 through 2016. Adopted from Bodilsen J, 
Dalager-Pedersen M, van de Beek D, Brouwer MC, Nielsen H. Incidence and mortality of brain abscess 
in Denmark: a nationwide population-based study. Clin Microbiol Infect. 2019 May 31;26(1):95–100 
This was driven by a substantial increase in the incidence of brain abscess patients 
>40 years of age. We also observed an increase in the proportion of brain abscess 
patients with immuno-compromise. During the study period, we found a decrease in 
1-year mortality from 29% to 20%, yielding an adjusted MRR of 0.44 (95% CI 0.31-
0.63). Fatal outcome was associated with advanced age, Charlson Comorbidity Index 
score >0, immuno-compromise, and congenital heart disease. 
 
4.5. STUDY V 
We matched 1,384 brain abscess patients with 13,838 population controls and 6,887 
appendicitis controls. Median follow-up was 5.9 years (interquartile range (IQR) 1.1-
14.2), 11.2 (IQR 4.8-19.8) and 11.3 (IQR 4.8-20.0). There were no substantial 
differences between population and appendicitis controls and the latter were omitted 
from further analyses.  
Mortality The observed 1-year, 2-5 year, and 6-30 year mortalities of brain abscess 
patients were 21%, 16%, and 27% versus 1%, 6%, and 20% for their matched 
population controls (Figure 9). The adjusted MRRs were 17.5 (95% CI 13.9-22.0), 
2.61 (95% CI 2.16-3.16), and 1.94 (95% CI 1.62-2.31). Results remained consistent 
regardless of age group (except for patients >80 years of age), previous comorbidity 
or not, and immuno-compromise or not. 
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Figure 9: Mortality of brain abscess patients and their matched population controls. Adopted from Bodilsen 
J, Dalager-Pedersen M, van de Beek D, Brouwer MC, Nielsen H. Long-term mortality and epilepsy in 
patients after brain abscess: A nationwide population-based matched cohort study. Clinical Infectious 
Diseases. 2019 Nov 27. 
 
Epilepsy Among 30-day survivors of brain abscess, the cumulative incidence of new-
onset epilepsy was 32% versus 2% in matched population controls (Figure 10). The 
risk remained substantially increased beyond six years of observation. 
 
 
 
47 
 
 
Figure 10: The cumulative incidence of epilepsy among brain abscess patients and their matched 
population controls. Adopted from Bodilsen J, Dalager-Pedersen M, van de Beek D, Brouwer MC, Nielsen 
H. Long-term mortality and epilepsy in patients after brain abscess: A nationwide population-based 
matched cohort study. Clinical Infectious Diseases. 2019 Nov 27. 
Comparisons of sibling cohorts of cases and population controls showed that only a 
small fraction of the difference in risk of epilepsy could be explained by family-related 
factors. 
EPIDEMIOLOGY OF BRAIN ABSCESS 
48
 
 
 
 
49 
CHAPTER 5. DISCUSSION 
The primary aim of this thesis was to describe the treatment and epidemiology of brain 
abscess. Treatment was examined in a literature review and the epidemiological traits 
by studies that used public, nationwide, and population-based registries.  
 
5.1. COMPARISONS WITH OTHER STUDIES 
Study I This is the first comprehensive review to summarise existing animal studies, 
as well as pharmaco-kinetic and clinical studies on treatment of brain abscess. 
Recommendations are in line with most previously published guidelines and 
textbooks, 43,49,51,52 although some differences exist, e.g. on duration of intravenous 
therapy and the need for follow-up treatment with oral antibiotics20,50. Common to all 
guidelines, the recommendations are largely based upon expert opinion and 
observational studies, given the lack of randomised clinical trials and scarcity of 
standardised pharmaco-kinetic studies of brain abscess treatment. 
Study II We have not been able to identify other studies examining the positive 
predictive value of ICD diagnosis codes in health care registries. In our study, the 
overall PPV (64%) of brain abscess diagnosis codes was poor to moderate. 
Erroneously coded hospital contacts were often seen among patients with CNS 
malignancy, intraspinal abscess and spondylodiscitis, or subdural empyemas. The 
results are vital for the conduct and interpretation of studies on brain abscess that rely 
upon ICD codes.  
Study III This is the first case-control study of risk factors of brain abscess. 
Nonetheless, our results confirm and quantify most suggested risk factors such as 
neurosurgery, ear-nose-throat infections, and congenital heart disease from previously 
published case-only studies from tertiary care centres (Tables 3 and 4). Compared 
with historic reports2,3,16,71, head trauma and chronic ear-nose-throat infections 
contribute less to the burden of this disease in our study. Using nationwide registries, 
we corroborate previous associations between risk of brain abscess and several 
immune-compromising conditions including organ transplant, HIV, and 
haematological malignancy60-63. We also show that numerous novel immuno-
modulatory treatments are substantial risk factors for brain abscess. 
Study IV We found a higher and increasing incidence of brain abscess (from 0.60 to 
0.90 per 100,000 person-years) during the study period compared with recent 
population-based studies from similar health care settings (0.3-0.4 per 100,000 
person-years; Table 1). Moreover, our results were confirmed by capture-recapture 
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analysis and supplemented by a search in a pathology register. In contrast to the only 
other nationwide population-based study using a large (insurance) registry in Taiwan, 
we applied a validated algorithm of diagnosis codes and excluded patients with 
intraspinal abscess19.  
Few studies of brain abscess have addressed mortality beyond case-fatality rates and 
most originate from single departments of neurosurgery. Importantly, we show that 
the mortality rate increases from 7% to 20% from 30 days to one year after admission 
for brain abscess. This is in line with findings from a few other existing studies 
reporting 1-year mortality15,18. 
Study V Previous studies on long-term mortality and risk of epilepsy after brain 
abscess are almost entirely of single-centre, historic patient cohorts with limited 
sample size and incomplete follow-up (Tables 3 and 4). No other studies have 
formally examined mortality beyond the first year since diagnosis and none included 
population controls for comparison of risk.  
We observed for the first time, that patients continue to have an increased risk of death 
for up to 30 years since diagnosis of brain abscess compared with their matched 
population controls. Using our large, contemporary cohort of brain abscess patients 
and accounting for competing risks, we also showed that the cumulative incidence of 
epilepsy is approximately 32% in these patients. Although one study has suggested a 
risk of epilepsy of 72% in brain abscess patients treated between 1939 and 1966, our 
results are consistent with most other single-centre and population-based studies 
(Table 4). 
 
5.2. METHODOLOGICAL CONSIDERATIONS 
Systematic and random error (chance) must be considered when assessing the internal 
validity of any observational study and suggestions of causality97. Systematic error is 
often categorised as selection bias, information bias, and confounding, while random 
error refers to the statistical accuracy of estimates97,98.  
 
5.2.1. SELECTION BIAS 
Selection bias is defined as systematic error related to the way study participants are 
included or factors that influence study participation97,98. The bias is important when 
observed associations between exposure and outcome differ considerably between 
study participants and non-participants. However, such differences are almost always 
unknown and selection bias should be inferred97.  
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Study I was conducted as a comprehensive narrative review and although great effort 
was made to include all relevant studies on the topic, a formal protocol for a systematic 
review was not applied. Moreover, the review is vulnerable to publication bias as well 
as the subjective assessment of importance by the authors. Nonetheless, we provided 
the terms used for our search in the United States National Library of Medicine 
(Pubmed) and accessed the database of a previous systematic review of published 
studies on brain abscess from 1970 until 201310.  
Study II is a cross-sectional study and may as such be vulnerable to selection bias if 
the study population is not representative of the background population. However, the 
Danish welfare system with tax-financed health care for all residents combined with 
the use of nationwide and population-based databases consisting of routinely collected 
information during every day clinical practice (i.e. the Danish National Patient 
Registry and electronic medical records), substantially reduces the risk of selection 
bias.  
All control populations for studies III and V were randomly selected using certain 
matching criteria from the Danish Civil Registration System, which encompasses the 
entire Danish population with less than 0.3% loss to follow-up85. This makes bias 
owing to the sampling procedures of controls and loss to follow-up virtually non-
existent.  
Study III was a case-control study and selection bias may be present if study inclusion 
of cases and controls depended on exposure status. Brain abscess patients were often 
more comorbid than their matched controls and hospital contacts are likely to be more 
frequent, whereby further comorbidities are diagnosed. Moreover, the diagnostic 
threshold is probably lower for these patients compared with persons without 
comorbidity, which could lead to selection bias. However, brain abscess is a fatal 
infection if left untreated and symptoms will progress until hospitalization or death. 
Thus, we consider any substantial differences in these events between cases and 
controls as very improbable. 
Study IV used an open (incidence part) and closed (1-year mortality) cohort design 
and patient inclusion depended upon the accuracy and completeness of brain abscess 
diagnosis codes. We used a validated algorithm of diagnosis codes for identifying 
brain abscess patients (Study II) in a nationwide register including all hospitals in 
Denmark. In addition, a capture-recapture analysis showed that incompleteness of 
brain abscess diagnosis codes did not significantly change incidence rates. The study 
period also spanned more than three decades and increased use of cranial imaging99 
and refined neurosurgical techniques7 may have contributed to increasing estimates 
of incidence. Still, a potential underestimation of the incidence of brain abscess during 
the beginning of the study period would only contribute to the overall conclusion that 
brain abscess is more frequent than previously believed. 
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For mortality rates, selection bias would be a serious concern if the association 
between the exposure (i.e. brain abscess) and the outcome (i.e. death) differed between 
study participants and non-participants, or in case of loss to follow-up. The negligible 
loss to follow-up in the Danish Civil Registration System has been mentioned 
previously. Importantly, we cannot rule out that the examined mortality rates of brain 
abscess patients not assigned a brain abscess diagnosis code or not included by our 
algorithm may differ from that of patients included in our study. To examine this 
further, we searched the Danish Pathology Registry in North Denmark Region and 
found only a few additional patients diagnosed with brain abscess at autopsy. 
Nonetheless, this may result in a slight underestimation of mortality rates. 
Study V is a matched cohort study and selection bias may substantially affect results 
if the association between exposure status (i.e. brain abscess) and outcomes (i.e. death, 
epilepsy) or loss to follow-up differed between study participants and non-
participants.  Again, the completeness of the Danish Civil Registration System 
practically excludes loss to follow-up and ensures unbiased registrations of mortality. 
For estimates of epilepsy, selection bias may influence the results if the occurrence of 
seizures differed between brain abscess patients included in our study compared with 
persons with brain abscess that remain undetected or were not included by our 
diagnosis code algorithm. Although our capture-recapture analysis and subsequent 
search in the Danish Pathology Registry yielded only a very limited of patients not 
identified by the Danish National Patient Registry, we cannot entirely exclude that 
some selection bias may have led to an overestimation in the cumulative incidence of 
epilepsy among brain abscess patients. 
  
5.2.2. INFORMATION BIAS 
Information bias includes misclassification of exposure, outcome or variables on 
potential confounders97. Non-differential misclassification denotes misclassification 
that is entirely independent of comparison groups whereas differential 
misclassification is present when misclassification differs between groups. If 
variables are dichotomous, non-differential misclassification will most often result in 
bias towards unity as opposed to differential misclassification where the direction and 
magnitude of bias is difficult to predict97. 
Study I A large degree of heterogeneity existed between studies including (lack of) 
definitions of clinical characteristics, measurements of antimicrobial concentrations, 
and outcomes. Moreover, studies rarely provided data on the outcome of treatment at 
the individual level. This hampers both comparisons and aggregation of data and often 
precludes firm conclusions on the optimal antibiotic regimen. 
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Study II We accessed the medical records of patients registered with brain abscess in 
the Danish National Patient Registry to examine the PPV of brain abscess diagnosis 
codes. Since all information in the medical records is entered prospectively on a day-
to-day basis by clinicians independent of future research projects, any 
misclassification of data between patients with confirmed or disproven brain abscess 
is likely non-differential and would thereby lead to conservative estimates of PPV. 
Similar considerations also apply for missing data, non-response bias, and recall bias. 
Moreover, we applied an a priori definition of brain abscess using variables readily 
available in the medical records in order to limit ascertainment bias, i.e. an assessor 
may be more willing to categorise patients with confirmed rather than disproven brain 
abscess in cases of doubt. This was also reflected by the distributions of definite 
(n=389), probable (n=41), and possible (n=14) brain abscess among the 444 patients 
with confirmed brain abscess. 
Studies III-V Misclassification of brain abscess, exposures, outcomes, or confounder 
data may have influenced the results of our registry-based studies. However, we used 
a validated algorithm to identify brain abscess patients and all information for cases 
and controls was retrieved in the same way using the same nationwide sources with 
virtually complete follow-up (Danish Civil Registration System)85,86 and high PPVs 
(Danish National Patient Registry)89,93. This reduces the impact of information bias 
and we expect most misclassification to be non-differentially distributed among cases 
and controls thereby driving estimates of relative risk towards the null.  
Nevertheless, some differential misclassification may be present in the case-control 
study. Including the index date in analyses of risk factors will often result in an 
overestimation of measures of relative risk (i.e. odds ratios) for cases versus controls, 
because the latter are unlikely to be hospitalised on the index date. Thus, controls 
cannot be assigned a hospital diagnosis of the examined risk factor in contrast to cases 
that are likely to receive a thorough diagnostic work-up during admission. Conversely, 
not including the index date may result in an underestimation of risk factors among 
cases.  
We tried to balance these two approaches by including the index date for short-term 
medical conditions with an immediate temporal risk of brain abscess (e.g. direct 
extension of ear-nose-throat infections) and not including the index date for more 
chronic conditions (e.g. diabetes mellitus, cancer or other immuno-compromising 
conditions), which may be undiagnosed in population controls at time of comparison.  
Similarly, estimates of epilepsy may also be subject to differential misclassification 
since the threshold for assignment of such a hospital diagnosis is likely lower for brain 
abscess patients than in their corresponding population controls. This could lead to an 
overestimation of the cumulative incidence of epilepsy in brain abscess patients 
compared with population controls. Yet, the overall PPV of diagnosis codes for 
epilepsy has previously been shown to be 89%100 and the incidence in the background 
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population (controls) is consistent with previous publications on the incidence of 
epilepsy in Denmark101. 
Finally, brain abscess patients were more comorbid prior to the index date than 
population controls, which is associated with frequent hospital contacts and even more 
complete coding of comorbidity. Such differential misclassification may potentially 
lead to both overestimation (i.e. surveillance bias) and underestimation of the impact 
of comorbidity on associations between brain abscess and risk factors or outcomes. 
Nonetheless, and as described previously, the PPV of the Danish National Patient 
Registry is generally very high89, and we consider this potential influence to be 
minimal.  
 
5.2.3. CONFOUNDING 
Confounding is a systematic error that occurs when an association between exposure 
and outcome is confused with or distorted by the effect of a third (confounding) 
factor97. The definition also requires the confounder to be associated with the exposure 
and outcome without being an intermediate link in the chain of causation between 
exposure and outcome97.  
Studies III-V Although we controlled for confounding by matching, stratification, 
and multivariate analyses, some residual and/or unmeasured confounding is likely to 
remain. Importantly, we did not have access to clinical data such as smoking status, 
overall dental hygiene, functional status, or clinical parameters including 
microbiological aetiology. Other examples of possible residual confounding include 
crude matching or categorisations of confounders, which may result in loss of 
information. On the other hand, we were able to match population comparison cohorts 
by age, sex, and municipality code, with the latter serving as a proxy for socio-
economic status. We also adjusted for several comorbidities in our analyses, thereby 
partly accounting for some of these potential confounders. Yet, unmeasured 
confounding may also have been introduced by adjusting for known confounders97.  
Other studies examining mortality of brain abscess have often identified clinical 
parameters such as abscess characteristics or intraventricular rupture of brain abscess 
as risk factors for death22,32,65,102-104. Although we acknowledge that such data are 
indeed of clinical importance, they often constitute part of the causal pathway leading 
from brain abscess to mortality, precluding them for use as confounding factors in 
adjusted analyses.  
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5.2.4. PRECISION 
For the results of studies II-V, we consistently provided point estimates with 95% CIs 
to account for random error (chance). This reporting carries a quantitative strength 
indicating both the magnitude and statistical precision of observed associations in 
contrast to simple dichotomous significance testing (with associated p-values). This 
approach has also been endorsed by most biostatistical authorities and journals 97,105-
107.  
The large sample size in studies II-V yielded statistically precise estimates with 
narrow 95% CIs for the primary objectives and for most subgroup analyses. Yet, 
sparse data still precluded detailed adjusted analyses in some strata (e.g. certain age 
groups and those with predisposing congenital heart disease).  
 
5.2.5. EXTERNAL VALIDITY 
Our studies were conducted within a tax-financed welfare state with unrestricted 
access to health care free at the point of delivery. This may reduce the generalisability 
of our results to other settings with more limited health care resources. However, as 
the aetiology, clinical presentation, treatment, and outcome of brain abscess is fairly 
homogenous across continents, we find it likely that our results are applicable to most 
other settings with comparable health care systems and infrastructure. 
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CHAPTER 6. CLINICAL IMPLICATIONS 
AND PERSPECTIVES 
This thesis highlights some of the challenges in the treatment of brain abscess and 
extends our existing knowledge on the incidence, risk factors, and prognosis of brain 
abscess.  
Our review of anti-infective treatment of brain abscess confirms that empirical therapy 
of community-acquired brain abscess in immuno-competent individuals should 
consist of a 3rd generation cephalosporin and metronidazole. Importantly, there are no 
randomised controlled trials to inform physicians on the optimal choice of anti-
infective drugs, and recommendations are largely based upon expert opinion and 
observational studies from tertiary care centres. Furthermore, the review emphasises 
the need for standardised pharmaco-kinetic studies of the intra-cavitary penetration of 
modern anti-infective drugs. Besides examining ratios of ‘area under the curve’ 
(AUC) between blood and pus, such studies should also address drug accumulation 
during treatment and the potential for early transition to oral antibiotics. Moreover, 
further clarification of the role of the blood-brain-barrier during early and late stages 
of brain abscess treatment is warranted.  
Nationwide and population-based health care registries in Denmark and other 
Scandinavian countries provide researchers with a unique and invaluable opportunity 
to examine both common and uncommon diseases on a large scale at a fraction of the 
cost and time spent if such data were to be acquired from clinical studies or databases. 
This is possible due to 1) the provision of universal health care by the welfare state, 
2) the possibility of individual linkage, and 3) a long tradition of longitudinal routine 
data collection108. At the same time, inherent risks of registry-based studies with large 
sample sizes include spurious associations without biological or clinical relevance109. 
Besides keeping such caveats in mind, careful evaluation of codes used also remains 
crucial as illustrated by the required algorithm to improve the PPV of brain abscess 
diagnosis codes in our validation study. Importantly, the study also showed that only 
54% of brain abscess patients were assigned a diagnosis and procedure code for brain 
abscess at a neurosurgical department, which emphasises possible selection bias in 
studies relying on ICD-10 codes for patient inclusion at selected hospital departments. 
Thus, further clinical studies are needed to improve our knowledge on the clinical 
presentation and outcome of all brain abscess patients. 
 
Our case-control study provides evidence of numerous risk factors for brain abscess 
supplemented by measures of importance on a societal level (i.e. population 
attributable fractions). These findings combined with the increasing incidence of brain 
abscess are important for clinicians and serve as an encouragement to maintain a low 
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threshold for performing a diagnostic work-up for this condition in vulnerable patient 
groups. In addition to a continued search for methods to improve preventive care, 
further characterisations of certain risk factors such as specific neurosurgical 
procedures, dental infections, or severity of immuno-compromise would be helpful to 
optimise patient care. Still, some questions remain unanswered. The relatively large 
proportion of patients with cryptogenic brain abscess (≈20%) and continued 
predominance of oral cavity bacteria as pathogens underlines the need for further 
scientific investigations into the pathogenesis of brain abscess that ultimately could 
help shed light on new ways to decrease the burden of this serious infection. 
Although we observed that both 30-day and 1-year mortalities have halved among 
brain abscess patients during recent decades, the 1-year mortality remains substantial 
at ≈20%. Moreover, brain abscess patients have a continued increased mortality for 
up to 30 years compared with the background population and almost one third of 
patients develop epilepsy during their lifetime. This is of considerable concern for 
clinicians and public health authorities and constitutes a major incentive to improve 
immediate as well as long-term clinical management of brain abscess patients. A 
prerequisite for such improvement should be the implementation of a specialised 
multi-disciplinary team of neurosurgeons, infectious diseases specialists, neurologist, 
and microbiologists at all centres treating these patients. Furthermore, large 
international collaborations are needed to examine promising new therapies including 
early transition to oral antibiotics and well-known surgical principles of abscess 
treatment such as continued drainage, irrigation, and intra-cavitary anti-infective 
treatment.  
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